Colossal Biosciences Seeks $20‑30B Valuation in New Funding Round

Colossal Biosciences, the high‑profile biotech firm known for its de‑extinction ambitions, has entered talks to secure a fresh round of financing. The company is targeting a valuation between $20 billion and $30 billion – roughly two to three times its most recent assessment – as it looks to expand its scientific and commercial operations.

The startup gained worldwide attention for its plan to resurrect extinct megafauna such as the woolly mammoth and the thylacine using cutting‑edge CRISPR gene‑editing, embryo culture, and artificial womb technologies. In its previous funding cycle, Colossal raised about $4.5 billion, which was allocated to building state‑of‑the‑art laboratories, hiring top‑tier researchers, and laying the groundwork for future re‑wilding projects.

The prospective capital infusion is expected to accelerate both research and market‑oriented initiatives. Beyond the headline goal of bringing back long‑lost species, the company envisions downstream applications in sustainable agriculture, climate‑change mitigation, and biodiversity restoration. Investors are therefore being pitched not only a bold scientific narrative but also a business model that could generate long‑term economic returns.

Industry analysts note that the lofty valuation reflects a blend of technical progress, public fascination, and the perceived commercial potential of resurrected organisms. Still, the venture faces significant ethical, ecological, and regulatory hurdles that could affect its trajectory. How Colossal navigates these challenges, allocates the new funds, and translates laboratory breakthroughs into real‑world outcomes will be closely watched by both the venture‑capital community and the broader scientific world in the months ahead.

Source: TechCrunch

ETİKETLER